LauraSimonsGrahamMD

Physician

Dr. Graham is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Laura Graham is a specialized Oncologist based in Aurora, CO, with an expertise in prostate cancer, kidney cancer, testicular cancer, urinary tract cancer, and internal medicine/oncology. She received her medical degree from Rush Medical College of Rush University Medical Center in 2015, then completed her internal medicine residency and a fellowship in Hematology and Medical Oncology at the University of Washington until 2021. She has several distinguished publications related to her field, with her work on mismatch repair deficiency in prostate cancer being cited by other publications 16 times. Dr. Graham is also a proud inductee to the Alpha Omega Alpha Honor Medical Society.

University of WashingtonFellowship, Hematology and Medical Oncology, 2018 - 2021
University of WashingtonResidency, Internal Medicine, 2015 - 2018
Rush Medical College of Rush University Medical CenterClass of 2015
University of ChicagoBA, Biological Sciences, 2005 - 2009

PubMed

Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations.
Stephanie Lakritz, Andrew Nicklawsky, Vida Alami, Manish Kohli, Chris Moskaluk
Clinical Genitourinary Cancer. 2025-02-01
Clinical and Genomic Features of Androgen Indifferent Prostate Cancer.
Jack Masur, Aakrosh Ratan, Krzysztof Wierbilowicz, Adanma Ayanambakkam, Michelle L Churchman
International Journal of Molecular Sciences. 2025-01-15
2 citations
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.
Laura S Graham, Nicholas C Henderson, Olesia Kellezi, Clara Hwang, Pedro C Barata
JCO Precision Oncology. 2024-08-01

Lectures

Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative trial in high risk localized prostate cancer (PC).
2019 ASCO Annual Meeting - 6/1/2019

SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 31st, 2018